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The Patentability of Antibodies for Use in Medications After Amgen v. Sanofi 
By: Kaitlyn Taylor 
Introduction 
 Taking medication is an important part of the daily routine of many individuals. For many, taking 
various medications, either prescription or over the counter, can prove to have a plethora of benefits such 
as fighting disease, managing chronic illness, and improving overall quality of life. Accordingly, a large 
number of medications enter the market every year. In 2020, 53 drugs received approval from the U.S. 
Food and Drug Administration (“FDA”),1 and as of October 2021, 37 medications received FDA 
approval.2 The process for researching and developing medications for approval and entrance into the 
market is incredibly long, arduous, and expensive.3 A critical step in this process is patenting the drug to 
protect the manufacturer's invention.  
There are many different patent types that allow pharmaceuticals to be patented; however, a 
recent case has caused a shift in how one particular class of pharmaceuticals, proprotein convertase 
subtilisin kexin type 9 (“PCSK9”) inhibitors, are patented.4 In February 2021, the U.S. Court of Appeals 
for the Federal Circuit ruled on Amgen v. Sanofi, an important case that will drastically impact the 
patentability of PCSK9 inhibitors.5 This case centered around patents for medications utilizing antibodies, 
which are also known as immunoglobulins.6 The court invalidated two Amgen patents covering PCSK9 
inhibitor monoclonal antibody drugs, used for lowering cholesterol.7 The antibodies utilized in Amgen’s 
drug, Repatha (generically known as evolocumab), lowers low-density lipoprotein ("LDL") cholesterol.8 
 
1See Food & Drug Admin., Novel Drug Approvals for 2020 (Oct. 8, 2021), https://perma.cc/6WGX-8LN7 (last 
visited Oct. 9, 2021). 
2See Food & Drug Admin., Novel Drug Approvals for 2021 (Oct. 8, 2021), https://perma.cc/7AEK-BRRT (last 
visited Oct, 9, 2021). 
3 Dani Kass, Pharma Giants Tee Up Biologics Innovation Fight At Fed. Circ. (Aug. 21, 2020) 
https://perma.cc/2QNH-7J6D (last visited Oct. 15, 2021). 
4 Amgen Inc. v. Sanofi, 987 F.3d 1080, 1082 (Fed. Cir. 2021). 
5 Id. at 1083. 
6 See NEIL A. CAMPBELL ET AL., CAMPBELL BIOLOGY 953 (Beth Wilbur et al. eds., 10th ed. 2014). 
7Jane Byrne, Amgen v. Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies, 
BioPharma Rep. (Mar. 25, 2021), https://perma.cc/4WHH-ETCD (last visited Oct. 9, 2021). 
8 Amgen, 987 F.3d at 1082. 
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Repatha can lower LDL cholesterol by binding to the PCSK9 protein and blocking PCSK9 from binding 
to LDL receptors.9  
In ruling on this case, the court stated that the functional claims within the patents for these 
antibodies were too broad.10 This ruling essentially eliminated the ability to define an antibody within the 
patent application purely based on the antibody’s function.11 This is a shift in the precedent previously 
governing the patentability of these monoclonal antibodies, which could impact and cause issues for 
applications and patents that were drafted several years ago, as well as future patents.12 Therefore, due to 
this shift in precedent, Amgen has and will continue to substantially impact the patentability of antibodies 
for use in medications. 
This article aims to discuss the impact that the Amgen decision has had, and will continue to have, 
on the process and patentability of antibodies for use in medications. Additionally, this article aims to 
discuss the impact that the Amgen decision could have on attempts to patent antibodies for use in new 
medications moving forward. This article is organized into five subsequent sections, the first of which 
will provide a brief overview of the United States patent system and background information regarding 
antibodies. After this, this article will provide an overview of the patentability of antibodies and the patent 
process regarding antibodies for use in medications prior to the Amgen decision. Then, this article will 
discuss and provide an overview of the Amgen case itself. Next, this article will discuss Amgen’s impact 
on the patentability of antibodies for use in medications and the patent process itself. Finally, this article 
will conclude with a section detailing the impact that the Amgen decision could have on future attempts to 
patent antibodies for use in new medications moving forward.  
Background 
A Brief History of Patents in the United States 
 
9 Id. 
10Jane Byrne, Amgen v. Sanofi ruling: It is time to kiss goodbye to broad, functional patent claims for antibodies, 
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 To discuss the patentability of antibodies, one must understand the patent system and process 
within the United States.  The Constitution of the United States laid out the initial framework for the 
governance of patents and patent law.13  “Congress shall have power . . . to promote the progress of 
science and useful arts, by securing for limited times to authors and inventors the exclusive right to their 
respective writings and discoveries.” (the “Intellectual Property Clause”).14 England’s approach in the 
Statute of Monopolies was the initial basis for this concept, which granted limited monopolies for 
inventions.15  
Although the Intellectual Property Clause initially set forth a basis for patent law, the first patent 
laws in the United States were not passed until the Patent Act of 1790 (“the 1790 Act”).16 The 1790 Act 
intended to promote the progress of the useful arts and grant a term of up to fourteen years of protection 
for inventions that could be deemed adequately important and useful.17 However, several years later, the 
1790 Act was repealed and replaced with the Patent Act of 1793, which contains the definition for what 
constitutes subject matter that is patentable, and this definition has predominantly remained unchanged.18 
There are four primary categories that define patentable subject matter: processes, machines, 
manufactures, and compositions of matter.19 Anything for which one is seeking patent protection must fall 
into at least one of these four categories.20 Additionally, patentable subject matter does not include 
abstract ideas, laws of nature, and natural phenomena.21 Therefore, anything that can be defined as one of 
 
13 A Brief History of Patent Law in the United States (May 7, 2014), https://perma.cc/C75E-Q466 (last visited Oct. 
9, 2021). 
14 U.S. CONST. art. I, § 8. 
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these exceptions is not patentable subject matter, even if it falls into one of the four previously mentioned 
categories.22 
The current patent system dictates that any individual who creates or discovers something that is 
“new and useful” may obtain a patent for that new invention.23 However, for a patent to be granted, an 
invention must satisfy three requirements.24 It must: (1) be novel, (2) have utility, and (3) be non-
obvious.25 In a patent application, the claim defines the patentable subject matter for which one is seeking 
protection.26 Claims function to describe and define precisely what would be protected if the patent 
application were to be granted so that it is clear exactly what is and what is not protected in regards to the 
patentable subject matter.27 Additionally, all patent applications must contain a written description 
supporting the claim of the invention and the process in which it is made using specific, clear, and concise 
terms, along with all of the other additional specifications as they are laid out in the written description 
requirement.28 In Amgen, the written description portion of the patents was the primary area of dispute 
and it is that portion where the court’s ruling had the greatest effect.29  
Another important aspect of the current patent system is the enablement requirement, which 
refers to a specific section of a patent application where one must describe how to make and use the 
invention.30 For this requirement to be satisfied, one who is skilled in the art must be able to make and use 
the invention that is defined within the claim in that patent application.31 Therefore, if a patent applicant 
has sufficiently informed one who is skilled in that particular art how to make and use the invention 
within the patent application, then the enablement requirement is satisfied.32 
 
22 Id. 
23 35 U.S.C.S. §§101-103 (2021). 
24 Id. 
25 Id. 
26 1824 THE CLAIMS [R-07.2015], https://perma.cc/JS94-DQ3F (last visited Oct. 15, 2021). 
27 Id. 
28 35 U.S.C.S. § 112 (2021). 
29 Amgen Inc. v. Sanofi, 987 F.3d 1080, 1084 (Fed. Cir. 2021). 
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What is an Antibody? 
 To discuss the patentability of antibodies, one must understand antibodies themselves. 
Essentially, an antibody is a protein component of the body’s immune system that circulates throughout 
the bloodstream and works to recognize and neutralize a plethora of foreign substances (called antigens) 
such as viruses and bacteria.33 Antibodies are proteins, and proteins are molecules that are made up of one 
or more polypeptides (a large group of amino acids) that are then folded and coiled into a three-
dimensional structure.34  Antibodies are produced and secreted by B cells which function as a part of the 
body’s adaptive immune system.35  
 Antibodies have a very distinct Y-shaped protein structure.36 This structure is made up of four 
polypeptide chains grouped into two identical pairs, two heavy chains and two light chains.37 These 
chains are linked together with disulfide bridges.38 Due to the Y-shaped structure of antibodies, the two 
“hands” serve as antigen binding sites while the “tail” binds to various receptors on the surface of the 
cell.39 The “tail” of an antibody cannot change, and thus is also known as its constant region; whereas, the 
hands of an antibody can change through the process of binding to antigens, and thus, are known as the 
variable region.40 Additionally, the “tail” of the antibody serves as the identifier to determine the 
antibody’s class.41 There are five different classes of antibodies: IgG, IgA, IgD, IgE, and IgM.42 Each 
antibody class serves a different purpose and has varying levels of frequency in the blood.43  However, the 
 
33 Antibody, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, https://perma.cc/47JH-CJQM (last visited Sept. 24, 
2021). 
34 See NEIL A. CAMPBELL ET AL., CAMPBELL BIOLOGY 953 (Beth Wilbur et al. eds., 10th ed. 2014). 




39 LAUREN M. SOMPAYRAC, HOW THE IMMUNE SYSTEM WORKS 4 (4th ed. 2012) 
40 Id. 
41 Id. 
42 Mark Chiu et al., Antibody Structure and Function: The Basis for Engineering Therapeutics, MDPI, Dec. 3, 2019, 
at 1, 2. 
43 Id. 
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vast majority of antibodies in the blood are IgG antibodies.44 The antibodies utilized in the drug Repatha, 
discussed in the Amgen case, are grouped in the IgG class of antibodies.45 
 In medications, antibodies serve a wide variety of purposes and functions, working to treat and 
manage symptoms of many different illnesses and conditions.46 Because of their high specificity in 
treating and managing illness, therapeutic antibodies used in medications have fewer adverse side effects 
when compared to traditional therapeutics.47 Due to this, therapeutic antibodies have become the 
predominant class of new drugs developed over the past several years, with many of the best-selling drugs 
worldwide utilizing antibodies.48 There are several different antibody engineering technologies used to 
develop these medications. However, the type of antibody in the medication at issue in Amgen, is a 
monoclonal antibody (“mAbs”).49 
 Monoclonal antibodies are produced by B cells, and they work to specifically target antigens.50 
When used in medication, mAbs should have several essential biophysical properties such as high 
stability, high binding activity for antigens, and low immunogenicity.51 One example of a monoclonal 
antibody is in the drug Humira (generically known as Adalimumab), which is in the IgG class of 
antibodies and generates a significant immune response.52  
 The monoclonal antibody whose patent was at issue in Amgen binds to PCSK9, which inhibits 
LDL cholesterol regulation.53 An elevated LDL cholesterol can cause heart disease.54 LDL receptors work 
to remove the amount of LDL cholesterol from the bloodstream, which serves as a regulatory method for 
 
44 LAUREN M. SOMPAYRAC, HOW THE IMMUNE SYSTEM WORKS 4 (4th ed. 2012). 
45 REPATHA PRESCRIBER INFORMATION, https://perma.cc/63QC-5LZ2 (last visited Sept. 24, 2021). 
46 MONOCLONAL ANTIBODY DRUGS FOR CANCER: HOW THEY WORK, https://perma.cc/8XGE-CGXB (last visited Oct. 
15, 2021). 
47 Ruei-Min Lu et al., Development of therapeutic antibodies for the treatment of diseases, J. Biomedical Sci., Jan. 
2020 at 1, 1 https://perma.cc/4U5Q-DGNL. 
48 Id. 
49 Amgen, 987 F.3d at 1083. 
50Ruei-Min Lu et al., Development of therapeutic antibodies for the treatment of diseases, J. Biomedical Sci., Jan. 
2020 at 1, 1 https://perma.cc/4U5Q-DGNL.  
51 Id. at 12. 
52 Id. 
53 Amgen, at 1083. 
54 Id. at 1082. 
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LDL cholesterol.55 PCSK9 works to regulate the degradation of LDL receptors by binding to the LDL 
receptors and mediating their degradation, which ultimately decreases the number of LDL receptors 
present on the surface of the cell.56 Antibodies, such as those utilized in Amgen’s drug Repatha, bind to 
PCSK9 and block it, allowing the LDL receptors to continue performing their regulatory function of LDL 
cholesterol.57 In binding to PCSK9 and inhibiting the binding of PCSK9 to LDL, this antibody increases 
the number of available LDL receptors, thereby lowering LDL cholesterol.58 
 The scientific definition, description, and understanding of antibodies are based primarily on the 
antibody’s protein structure and primary function.59 However, the legal definition and understanding of 
antibodies as it relates to patentability is slightly different.60 When it comes to the patentability of an 
antibody, the legal system views that antibody merely as it is described and defined within the elements of 
its claim.61 With Repatha, scientifically, the antibodies in this medication would be described based upon 
their function, to bind to PCSK9 and thereby lower LDL cholesterol.62 However, legally, they would be 
defined based upon how they are described in the written claims portion of the patent pertaining to this 
drug: an isolated monoclonal antibody that when bound to PCSK9, binds to one of many residues.63 This 
demonstrates a difference in the understanding, description, and definition of an antibody between the 
scientific and legal perspectives. The scientific understanding is based on the antibody’s structure and 
function whereas the legal understanding is based upon the claims in the antibody’s patent application. 
These differences could lead to a misunderstanding regarding what is actually claimed and therefore 
protected by a particular patent. This then leaves room for the United States Patent and Trademark Office, 
 
55 Id. 
56 Id. at 1083. 
57 Id. 
58 REPATHA PRESCRIBER INFORMATION, https://perma.cc/63QC-5LZ2  (last visited Sept. 24, 2021). 
59 Antibody, NATIONAL HUMAN GENOME RESEARCH INSTITUTE, https://perma.cc/47JH-CJQM (last visited Sept. 24, 
2021). 
60 MONOCLONAL ANTIBODY PATENTS: EVOLVING LAW & STRATEGIES, (Oct. 1, 2012) https://perma.cc/BC96-CWY7 
(Oct. 15, 2021). 
61 Id. 
62  REPATHA PRESCRIBER INFORMATION, https://perma.cc/63QC-5LZ2  (last visited Sept. 24, 2021). 
63 Amgen, at 1083. 
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as well as the court system, to deal with these discrepancies and disputes as they arise, clarifying for 
scientists exactly what they have and have not claimed in regard to the antibodies they are attempting to 
patent.  
How were Antibodies Patented in the Past? 
 To discuss the changes to antibody patentability following the decision in Amgen, one must also 
understand the process of patenting antibodies prior to this decision. As mentioned previously, all 
inventions to be patented must meet three criteria: (1) novelty, (2) utility, and (3) nonobviousness, and 
this includes antibodies for use in medications.64 Additionally, all inventions to be patented must adhere 
to the written requirements and disclosures of 35 U.S.C.§ 112.65 However, satisfying this written 
requirement is often the primary focus of litigation in patent suits where individuals claim infringement of 
antibody patents as used in medication.66 In these suits, courts must determine what level of specificity 
must be listed within the claim to adequately satisfy the written requirement laid out in 35 U.S.C. § 112.67 
This discussion of the written requirement, specifically the enablement requirement, and whether or not 
these requirements are satisfied, is the primary focus of the litigation in the Amgen case.68 
Georges J. F Köhler and César Milstein were the first individuals who introduced a technique that 
allowed for the creation of monoclonal antibodies in large amounts.69 However, the pair of scientists were 
not able to obtain a patent for their techniques, given that their work had been featured in an article in 
Nature, and British patent law prevents any work that has been previously disclosed in a medium such as 
a publication from being included in an application for a patent.70 Additionally, they did not obtain a 
patent in the United States, as they took no action to file for a patent.71 The first patents in the United 
 
64 35 U.S.C.S. §§ 101-103 (2021). 
65 35 U.S.C.S. § 112 (2021). 
66 Laura Labeots, The Written Description Requirement, Healthcare Law Insights, Dec. 17, 2014, 
https://perma.cc/M379-GUDF (last visited Oct. 15, 2021). 
67 Id. 
68 Amgen, 987 F.3d at 1083. 
69 Ruei-Min Lu et al., Development of therapeutic antibodies for the treatment of diseases, J. Biomedical Sci., Jan. 
2020 at 1, 1 https://perma.cc/4U5Q-DGNL. 
70 A Missed Opportunity? The Patent Saga, WHAT IS BIO TECHNOLOGY (2017), https://perma.cc/SAC4-N2GT. 
71 Id. 
8
The University of Cincinnati Intellectual Property and Computer Law Journal, Vol. 6, Iss. 1 [2020], Art. 7
https://scholarship.law.uc.edu/ipclj/vol6/iss1/7
9 
States for monoclonal antibodies used in a clinical setting (to fight tumors and influenza virus antigens) 
were awarded a few years later in late 1979 and early 1980 to Koprowski, Croce, and Gerhard.72 This was 
controversial in Britain as well as the scientific community at large given that many individuals felt as 
though they were merely copying Köhler and Milstein’s technique.73 After this patent was granted, claims 
shifted from patenting the process of creating the antibody utilized in a particular medication, to claims 
that were instead focused on patenting the antibody itself. 
There is a substantial body of law that relates either to the patenting of antibodies or the written 
requirement portion of the patent application process. Given that this body of law is so large, this article 
will highlight only a few significant cases that provide important background and precedent on these 
issues before the ruling in Amgen. The following four cases will provide insight and understanding into 
the process of patenting antibodies as well as the court’s understanding and interpretation of the written 
requirement portion of the patent application process. 
This first case provides a general insight into the patenting of monoclonal antibodies. In a 2015 
case before the U.S. District Court for the Eastern District of Virginia, the plaintiff, UCB, brought suit 
against Yeda Research & Development Company, stating that UCB’s monoclonal antibody drug, Cimzia, 
did not infringe on Yeda’s patent and that Yeda’s patent was invalid.74 The court held that in the written 
description, using the term “monoclonal antibody” limited the term to an antibody that was generated in a 
specific manner and not through other processes.75 The court further defined a monoclonal antibody as a 
grouping of a single type of antibody that was generated in that specific manner.76 This case essentially 
set up the court’s interpretation of a monoclonal antibody as it was defined through the written 
requirement of a patent application.77 This interpretation by the court provided a standardized method of 
 
72 Id.  
73 Id. 





Taylor: The Patentability of Antibodies for Use in Medications After Amge
Published by University of Cincinnati College of Law Scholarship and Publications, 2020
10 
determining exactly what a monoclonal antibody is so that it does not need to be continuously defined in 
future applications.78 
 Regents of Univ. of Cal. v. Eli Lilly & Co., provides a baseline analysis and understanding 
regarding the courts’ interpretation of the written requirement of the patent application. 119 F.3d 1559 
(Fed. Cir. 1997). In this case, the Regents of the University of California brought action against Eli Lilly 
& Company alleging infringement on several patents for the manufacture of human insulin.79 The court 
cited several different specifications for adequately fulfilling the written description requirement in a 
patent application.80 First, the court stated that a patent application must describe an invention in 
sufficient detail to conclude that “the inventor invented the claimed invention.”81 This “sufficient detail” 
is satisfied through a plethora of descriptive means such as words, structures, diagrams, formulas, 
chemical names, or physical properties.82 When it comes to deoxyribonucleic acid (“DNA”) that codes for 
a specific protein, the court stated that in order to claim DNA in a patent application, a very precise 
definition is required.83 This definition should be precise because the disclosure of the amino acid 
sequence of a protein does not necessarily make the DNA molecules that are encoding the protein 
apparent. The DNA molecules that encode the protein are not apparent because the genetic code is 
redundant and could generate a large number of DNA sequences that code for the protein.84 Additionally, 
the court noted that a definition by function does not define the genus itself, as it describes what it does as 
opposed to what it is.85 Ultimately, this case indicates that in order to satisfy the written requirement, a 




79 Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1562 (Fed. Cir. 1997). 
80 Id. 
81 Id. at 1566. 
82 Id. 
83Id. at 1567. 
84 Id. 
85 Id. at 1568. 
86 Id. 
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 The next case discussed, Centocor Ortho Biotech, Inc. v. Abbott Labs., 636 F.3d 1341 (Fed. Cir. 
2011), provides insight into a portion of the written requirement of a patent application that is often 
referred to as “the antibody exception.”  In this case, Centocor brought suit against Abbott Labs alleging 
infringement on a medication that utilized antibodies to treat arthritis.87 The court referenced the 
description guidelines from the U.S. Patent and Trademark Office (“USPTO”) discussing the “antibody 
exception.”88 These guidelines indicated that a claim referencing an isolated antibody capable of binding 
to a specific protein is described adequately if the specification fully characterizes the protein and that this 
claim does not need to include working or detailed example(s) of actual antibodies that bind to the 
protein.89 The court then elaborated that this example (which is often referred to as the antibody 
exception), assumes that the patent applicant is first disclosing a new protein and then claiming both the 
antibody that binds to it and the protein itself.90 Finally, the court indicated because precedent implies the 
written description requirement for antibody claims can be satisfied through the disclosure of an antigen 
that is well-characterized, so can antigens that are newly characterized, so long as the antibody creation 
that is claimed is routine.91  
 The Centocor case set forth the precedent for the “antibody exception,” which led to many broad 
antibody claims regarding the written requirement. In the area of patent law, a traditional interpretation of 
the written description requirement would have required a characterization of the antibody that was more 
specific than the broad claims permitted because of Centocor. However, the antibody exception set forth 
the precedent that if the applicant can characterize the structure of an antigen, then the applicant can claim 
an antibody against the antigen.92 The “antibody exception” doctrine, as first defined in Centocor, 
described the relationship like a “lock and key” mechanism, to mean that if an antigen can be 
 
87 Centocor Ortho Biotech, Inc. v. Abbott Labs., 636 F.3d 1341, 1343 (Fed. Cir. 2011). 
88 Id. at 1351. 
89 Id. 
90 Id. 
91 Id. at 1352. 
92 Monoclonal Antibody Patents: Evolving Law & Strategies, FENWICK INSIGHTS, (Oct. 1, 2012) 
https://perma.cc/5ZPJ-L5TV. 
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characterized to a certain level of detail, then the creation of an antibody that would bind to that antigen 
would be straightforward.93   
 AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., provides insight into patenting 
antibodies generally, as well as patenting a genus or group of antibodies. 759 F.3d 1285 (Fed. Cir. 2014). 
In this case, AbbVie sued Janssen Biotech, alleging infringement on several patents that Janssen 
possessed on a human IL-12 neutralizing antibody drug that was marketed under the name Stelara.94 
AbbVie’s patent claimed a class of antibodies defined by their high affinity and neutralizing activity to a 
known antigen, human IL-12.95 The court had to determine if the patents at issue sufficiently described 
the representative species to support the entire genus of the antibodies.96 The court concluded that 
AbbVie’s patents described only one type of antibody that was structurally similar, not an entire genus.97 
However, the court noted that claims that functionally define a genus can be vulnerable to a challenge for 
lack of written support, especially in fields where the technology claimed is highly unpredictable.98 This 
vulnerability exists because it can be difficult to establish that a correlation exists between the function 
and structure for an entire genus and precisely what the functionally claimed genus would cover.99  
Importantly, the AbbVie case served to narrow the “antibody exception” for the written disclosure 
requirement, as it indicated that in order for this requirement to be satisfied and an applicant have the 
ability to claim a genus, that applicant would need to disclose all of the potential antibody structures that 
the patent intends to cover.100 This narrowing of the antibody exception led to a shift where many 
companies would include the amino-acid sequences in their disclosure, labeled as residues of the target 
antigen of the antibody, which was the case for the patent application in Amgen.101 
 
93 Id. 
94 AbbVie Deutschland GmbH & Co. v. Janssen Biotech, Inc., 759 F.3d 1285, 1289,1292 (Fed. Cir. 2014). 
95 Id. at 1299. 
96 Id. 
97 Id. at 1300. 
98 Id. at 1301. 
99 Id. 
100 Id. 
101 Amgen Inc. v. Sanofi, 987 F.3d 1080, 1083-84 (Fed. Cir. 2021). 
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Amgen v. Sanofi 
 The Amgen case had a long history of ongoing litigation beginning October of 2014 when 
Plaintiffs, Amgen, Inc., Amgen USA Inc., and Amgen Manufacturing, Ltd., filed suit in the U.S. District 
Court for the District of Delaware, alleging that Defendants, Sanofi, Sanofi-Aventis U.S. LLC, Regeneron 
Pharmaceuticals, Inc., and Aventisub LLC infringed several of the plaintiffs’ U.S. patents.102 These 
patents were then tried based on their validity in front of a jury in March of 2016, where the district court 
granted judgement as a matter of law based upon nonobviousness and a lack of willful infringement.103 
Notably, the jury found that the patents were not invalid due to a lack of written description.104 Sanofi 
appealed, and the U.S. Court of Appeals for the Federal Circuit found that the district court erred in 
finding that the patents were valid.105 As a result, the U.S. Court of Appeals for the Federal Circuit 
remanded back to the lower court for a new trial on the issues surrounding Sanofi’s defense that the 
patents in question lack both the enablement and written description requirements.106 On remand, the 
district court found that Sanofi’s claims were invalid for a lack of both written description and 
enablement, which the Federal Circuit Court ultimately affirmed.107  
 Amgen owns the two patents at issue in this case: U.S. Patent No. 8,829,165108 (commonly 
referred to as the “'165 patent”) and U.S. Patent No. 8,859,741109 (commonly referred to as the “'741 
patent”).110 These patents describe the antibodies utilized in Repatha, where antibodies lower LDL levels 
by binding to PCSK9 and preventing it from binding to LDL receptors.111 They share a common written 
description, specifying that the antibody to be patented is an isolated monoclonal antibody, and that when 
 
102 Amgen Inc. v. Sanofi, Civil Action No. 14-1317-RGA, 2019 U.S. Dist. LEXIS 146305, at *2 (D. Del. Aug. 28, 
2019). 
103 Amgen, 987 F.3d at 1083-84. 
104 Id. at 1084. 
105 Id. 
106 Id. 
107 Id. at 1084, 1088. 
108 U.S. Patent No. 8,829,165 (issued Sept. 9, 2014). 
109 U.S. Patent No. 8,859,741(issued Oct. 14, 2014). 
110 Amgen, 987 F.3d at 1083. 
111 Id. 
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bound to PCSK9, the antibody binds to at least one (or more) of a list of 15 amino acids (described as 
residues).112 The written description also includes amino acid sequences for 26 antibodies, one of which is 
the antibody utilized in Repatha.113 Additionally, the written description discloses the three-dimensional 
structures for two antibodies and the location where those two antibodies bind to PCSK9.114 
 The primary area of the court’s analysis in Amgen is in determining if the claim at issue satisfies 
the requirements in 35 U.S.C. § 112.115 The court initially focused on the enablement requirement, stating 
that to prove the invalidity of a claim due to a lack of enablement, one must present clear and convincing 
evidence that a person of ordinary skill in the art would have to undergo “undue experimentation” to 
practice this claimed invention.116  
The court then turned to the eight Wands factors, which establish a factual method of analyzing 
whether undue experimentation is necessary.117 The Wands factors are: (1) the amount of necessary 
experimentation, (2) the amount of either guidance or discretion that is presented, (3) the existence (or 
lack thereof) of working examples, (4) the nature of the invention itself, (5) the state of similar preexisting 
art, (6) the skill of those who are in the art, (7) the predictability (or lack thereof) of the art, and (8) the 
breadth of the claims at stake.118 Amgen argued that under these factors, no undue experimentation is 
necessary to obtain the antibodies that are within the scope of the claims, whereas Sanofi argued that 
undue experimentation is necessary.119  
The court stated that applying the Wands analysis requires the concrete identification of some or 
all of the embodiments asserted to not be enabled.120 This must occur in order to concretely demonstrate 
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use the product or processes in question.121 The court also held that, “while functional claim limitations 
are not necessarily precluded in claims that meet the enablement requirement, such limitations pose high 
hurdles in fulfilling the enablement requirement for claims with broad functional language.”122 The court 
essentially indicated that it is incredibly difficult to fulfill the enablement requirement in claims where 
broad function language is used.123 This broad functional language is like the language used to describe 
the antibodies to be patented in this case.124 The court highlighted that the claims in this case are defined 
by functional limitations as opposed to structure, indicating that the functional breadth of the antibodies in 
question was a major source of concern.125 Ultimately, the court agreed with the district court that the 
level of specification present in these claims did not enable preparation without undue experimentation.126 
The court highlighted that in limiting the claims to how and what the antibodies bind to, this factor alone 
would be sufficient to require one of ordinary skill to experience undue experimentation.127 
Notably, the court did mention one mitigating factor although it did not have a drastic impact on 
the decision itself.128 The court recognized that the field of science where several patents were at issue is 
unpredictable in terms of satisfying the full scope of functional limitations necessary under 35 U.S.C. § 
112.129 
Ultimately, the court held that undue experimentation would be necessary to practice the full 
scope of the claims at issue in this case.130 The court stated that the primary reasoning for this decision 
was that the evidence demonstrated that the scope of the claims at issue encompassed millions of potential 
candidates that are claimed with respect to a multitude of specific functions.131 As a result, generating and 
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screening each antibody candidate would be necessary to determine if that candidate adheres to the 
necessary limitations set forth by the claim stating the dual-function of each antibody.132 Additionally, the 
court stated that the Wands factors do not indicate that the screening of antibodies never requires undue 
experimentation.133  
Essentially the ruling in Amgen indicated that broad functional language would no longer be 
acceptable to satisfy the enablement requirement as laid out in 35 U.S.C. § 112, since language such as 
this would require “undue experimentation” by a person having ordinary skill in the art to practice or use 
the claimed invention.134 The court’s reasoning came from its analysis of the Wands factors, 
which indicated that Amgen’s broad functional patent claims, given the breadth of those claims, set the 
bar too high under the enablement requirement.135 The court indicated that had the claims been based 
upon structure as opposed to function, the outcome could have been different.136 The court noted that the 
analysis using the Wands factors in and of itself did not indicate that antibodies never require undue 
experimentation.137 In Amgen, the Federal Circuit held that in order for one to obtain broad patent 
coverage for a class of antibodies that perform a specific function and bind to a specific antigen, one must 
meet one of two criteria.138 A company must disclose an adequate number of antibodies that are 
representative of this function across the genus one is attempting to claim, or establish that a clear 
relationship exists between the antibody’s function and the genus of the antibody that is present in the 
company’s specification.139 Ultimately, the ruling in Amgen provided a stark contrast to claims where 
antibodies used in medications had been patented in the past, given that broad functional claims had 
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protecting antibody inventions as the amount of data required when disclosing and claiming antibodies 
has significantly increased with the court’s decision in Amgen.141 
How Has/Will the Amgen Decision Impact the Process and Patentability of Antibodies? 
 As the Amgen v. Sanofi decision indicated that broad functional claims are no longer acceptable 
or sufficient to satisfy the enablement requirement of a patent application for antibodies, this begs the 
question: how has and how will this decision impact both the process and patentability of antibodies for 
use in medications? In the United States, six of the top ten drugs, when ranked by revenue, are drugs 
utilizing antibodies in some way.142 Due to the Amgen decision, it is estimated that there will likely 
continue to be patentability issues surrounding antibody patents and patent applications that were drafted 
several years prior to the court’s decision in Amgen.143 As the decision in Amgen v. Sanofi shifted how 
antibodies are patented and what antibody claims are sufficient to satisfy both the written and enablement 
requirements, this could endanger the patent protection of not only those medications, but others that are 
currently patented as well as those that have yet to be patented.144 This shift in what is considered 
sufficient to satisfy the necessary requirements to patent an antibody drug has already and will likely 
continue to impact the process of patenting antibodies, as well as encourage companies to get creative in 
searching for alternative methods for protecting their antibody medications. 
 Any major decision in a particular area of law is bound to impact future analysis or thought 
within that area. Therefore, the same can be said regarding the process of patenting antibodies for use in 
medications. The decision by the Federal Circuit in Amgen substantially “raised the bar” for obtaining 
broad patent protections of monoclonal antibodies used in therapeutics to satisfy the enablement 
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requirement of a patent application.145 Additionally, the standard regarding the patent’s specification as a 
part of the written description requirement was also increased because of Amgen.146  This higher bar for 
both the written description and enablement requirement from the Amgen decision creates a list of 
additional demands that those seeking patent protection of antibodies must meet, which will likely create 
some challenges in regards to the process and patentability of monoclonal antibodies used in 
therapeutics.147 For example, because of the Amgen decision, it is likely that patent examiners will 
become much more conservative when it comes to their grants.148 As a result of this, patent examiners are 
likely to reject these broader claims for the patenting of antibodies.149 Therefore, individuals who are 
seeking to patent an antibody would have to fight for their application through the Patent Trial and 
Appeal Board, and eventually, the Federal Circuit.150 This higher bar for antibody medication patent 
protection would ultimately make it more difficult for those seeking patent protection to obtain an 
antibody patent, as it would require additional time, money, and research in order to satisfy the new 
antibody patenting requirements following the Amgen decision.151 
Although Amgen created its own set of difficulties and issues moving forward, there are clear 
positive impacts that may come about. One positive impact is the increase in competition because the 
Amgen decision suggests that there are ways that companies will be able to either invent around or 
challenge a claim that prevents them from inventing around a patent for a given antibody patent that 
achieved the same goal first.152 This will then lead to an increase in competition, which is not inherently a 
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negative outcome from this decision as currently there is not a significant amount of competition when it 
comes to biologics, such as medications that utilize antibodies.153  
Not only could the Amgen decision lead to an increase in competition, it could also lead to an 
increase in innovation.154 Had the Amgen decision allowed broad functional claims to continue to remain 
valid, it could have prevented other companies from making improvements within that class of antibodies 
in the future.155 Often when a particular class of antibodies is being developed for therapeutic drug use, 
each subsequent antibody created within that class has one, if not more, additional or enhanced 
feature(s).156 If the broad functional claims over an antibody class, like those in Amgen, were upheld, this 
could prevent these incremental improvements within a particular antibody class from being developed 
due to infringement as they would still be present within the same antibody class.157 Therefore, the Amgen 
decision could lead to an increase in innovation as subsequent incremental improvements on a class of 
antibodies would not constitute infringement on a patent for the entire class.158 This would be beneficial 
for patients as it would allow for the creation of more effective medications that were able to treat and 
manage illness and symptoms more effectively. Therefore, the Amgen decision will likely lead to an 
increase in innovation as it will create an incentive for companies to be more innovative in their 
development of antibody medications, but this incentive comes from the inability to secure patent claims 
that are broad and purely functional, failing to adequately describe the structures disclosed.159  
 Additionally, although the Amgen decision will pose some difficulties and challenges for those 
companies who are trying to obtain an antibody patent for a particular medication, this prevents those 
seeking antibody patents from claiming more than they have actually discovered.160 Getting rid of the 
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ability to broadly claim more than what one has truly discovered could lead to the lowering of the price of 
medications utilizing antibodies, which could prove to greatly benefit patients.161 In obtaining a large 
number of extremely broad patents, companies are able to pile on protections of the new drug they are 
creating.162 Obtaining a large number of broad patents will keep competitors who would be able to 
produce the same drug for a lower cost out of the market for a significant period of time.163 This leads to a 
substantial amount of income for the companies that hold these broad antibody patents.164 In making it far 
more difficult, if not impossible, to obtain these patents, competition will be increased within the market 
for medications that utilize antibodies, thus lowering prices for patients.165 
 Ultimately, the Amgen decision has altered the way antibodies for use in medication are patented, 
through preventing broad functional claims from continuing to satisfy the enablement requirement. 
Although this will inevitably make it more difficult for companies to obtain patents for antibody drugs, it 
also will likely have several positive effects that will ultimately help patients, such as, those relating to 
competition, innovation, and lowering prices for patients. As a result of these difficulties created in the 
wake of the Amgen decision, it is possible that some companies will instead turn to alternative methods in 
order to avoid these difficulties caused by the Amgen decision. 
Alternative Methods of Antibody Protection  
Given that it is unclear how antibodies claimed at the genus level for use in medications can be 
patented following the Amgen v. Sanofi decision, companies may turn to alternative methods outside of 
the patent process of claiming an entire genus of antibodies to seek protection over their antibody drugs 
that perhaps would otherwise have a low patentability. There are a plethora of various methods that could 
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the Amgen decision.166 The top three methods include: trade secret protection, attempting to patent the 
antibody based on homology, and accession deposits, among many others.167 Each of these methods has 
benefits as well as drawbacks, and the costs and risks associated with these options compared to the 
process in which antibodies were patented in the past will need to be weighed carefully by each company 
seeking protection over a particular antibody drug.168 
There are several alternative methods of antibody drug protection that still involve the patent 
process yet avoid the broad functional claims that are no longer permitted under the Amgen decision. 
These methods, if utilized by companies seeking protection of their antibody drugs, could still allow for 
patent protection, although the claims within the patent application would not be broad or merely 
functional. One example of an alternative method of antibody drug protection utilizing the patent system 
would be to patent a specific antibody sequence and antibody sequences that share a certain level or 
similarity or homology with those original antibody sequences.169 This process of patenting through 
homology could provide a method of protecting the sequence that creates the antibody itself.170  
Another option would be for companies to obtain a patent that protects everything except the 
antibody itself.171 This patent could include methods of manufacturing the medication, the pharmaceutical 
composition of the antibody drug, and other aspects of the medication that do not include the antibody 
itself.172 However, this alternative is not without flaw, as it too could raise several questions regarding 
functional claims which could potentially cause issues rooted in the court’s decision in Amgen.173  
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The patent system provides another option for those seeking robust patent protection of a 
monoclonal antibody medication, the layering process.174 The concept and process of layering involves 
both the filing of multiple patents and multiple claim scopes temporarily.175 Protecting antibody drugs and 
obtaining patent protections could be achieved in several different ways.176 For example, the subject 
matter of each patent “layered” should be claimed using a variety of different formulas which create 
differences in scope.177 This way, even if some of the claims are invalidated as a result of a post-grant 
challenge, the other claims that were presented within the patent application would remain valid.178 
Furthermore, the patent portfolio could be staggered chronologically so that a range of different patent 
claims are included within the portfolio, thus extending the term in which the patent application was 
initially filed.179 
Additionally, adding back up claims is another method that can be utilized within the patent 
process to help increase the patentability of antibodies following the court’s decision in Amgen where 
broad functional claims were deemed to be insufficient to secure patent protection for antibody 
medication would be adding backup claims.180 When a patent applicant adds backup claims, they are 
essentially also including a set of narrower claims within the patent application.181 These narrower claims 
include various aspects of the antibody such as portions of the antibody’s sequence or combining 
functional and structural elements within the same claim, which will increase the patent’s chance of 
withstanding a challenge, and therefore the patentability of the antibody.182 In adding these backup claims 
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to the patent application for an antibody drug, companies would be increasing the patentability of that 
drug as it would magnify the chances that the entire patent is invalidated in a post-grant challenge.183 
Another example of an alternative method would be to utilize trade secret protection.184 The U.S. 
Food and Drug Administration provides twelve years of exclusivity through the trade secret process, and 
companies may simply hold on to their inventions as trade secrets for this time, skipping the patent 
process entirely.185 Although this solution would avoid the risks associated with disclosing information 
through the patent process in regards to how their antibody medications achieve the desired result, it also 
presents its own challenges.186  However, utilizing trade secret protection as an alternative solution to 
claiming patent protection could raise questions regarding the Biologics Price Competition and 
Innovation Act, as well as questions regarding biosimilar competition.187 These questions present a 
problem as without a patent disclosing exactly what the antibody is designed to bind to, it would then 
need to be determined if that information regarding the antibody’s function, which would potentially be 
protected as a trade secret, would need to be disclosed through the Biologics License Application 
approval process.188 Additionally, it would require a determination of whether or not biosimilars would or 
should have access to that potentially protected information or not.189  Protecting antibody medications 
through trade secret protection presents a problem as it could prevent the dissemination of information 
and advancements in regard to future antibody medication developments. Preventing information about 
future antibody medications from being shared would go against the further production of science and the 
overall goal of improving medications for future use. The issues caused by protecting antibodies with 
trade secret protection demonstrates that although the patent process regarding antibody medications will 
prove to cause difficulties for companies looking to patent medications in the future, alternative solutions 
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may not prove to be the best solution for combating these difficulties, as they could create a variety of 
additional problems. 
One final alternative method outside of the patent process of claiming an entire genus of 
antibodies to seek protection over an antibody drug that perhaps would otherwise have a low patentability 
is an accession deposit. An accession deposit occurs when a company takes a sample of the antibody for 
which they are seeking protection and deposits this sample at an accession deposit organization.190 Then, 
the company would use that deposit at the accession deposit organization as a reference for their patent 
claims in the process of patenting the antibody.191 This process is rarely done and, likely would not occur; 
however, it still is a potential option that a company could use when seeking an alternate method of 
antibody medication protection following the Amgen decision.192 
Ultimately, these alternative methods to the new standards for monoclonal antibody medication 
patent protection in the wake of the Amgen decision all have benefits as well as downsides, and each 
method of protection is associated with varying levels of risk. Although some companies may choose to 
seek alternative methods or layer in additional protections to their patent applications so that their 
antibody drugs will have an increased likelihood of patentability due to the changes and increased 
difficulties caused by the Amgen decision, it is highly unlikely that these changes in patent protections 
will cause pharmaceutical companies to stop making antibody drugs.193 As mentioned previously, 
antibody drugs are massively profitable, with some bringing in tens of billions of  U.S. dollars a year.194 
Although these alternative methods may provide a way for companies to obtain additional patent 
protection or avoid some of the difficulties of the changes caused by Amgen, companies will likely still 
seek to create and obtain protection for these antibody medications, regardless of their patentability. 
How Will the Amgen Decision Impact Future Attempts to Patent Antibodies? 
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 Now that a thorough discussion has occurred in regard to the impact that the Amgen v. Sanofi 
decision has had and will continue to have on the process and patentability of antibodies, one question 
still remains: how will this decision impact future attempts to patent antibodies for use in medications? As 
mentioned previously, the debate over whether antibodies can be claimed and protected by a patent 
broadly at the genus level has been ongoing.195 Those in support of claiming antibodies at a genus level 
have based their argument around the idea that since scientists have a tendency to define antibodies based 
on what they bind to.196 However, the Federal Circuit, in the Amgen decision has strongly indicated, so 
much so that it can no longer be questioned, that there is no longer an exception present for antibodies, 
indicating that antibodies can no longer be claimed or under patent protection at the genus level in the 
way that they were previously.197 Ultimately, this shift will make it more difficult for patent applicants to 
obtain patent protection for their monoclonal antibody drugs. However, this increase in difficulty will also 
help to avoid some of the previously mentioned problems that can occur as a result of permitting genus 
level patent claims. 
 As a result of the Federal Circuit’s decision in the Amgen case, future attempts to patent 
antibodies will be affected by this shift.198 Following the Amgen decision, companies will no longer be 
able to define and claim antibodies purely based on function alone.199 Those looking to patent antibodies 
moving forward will have to tie their patent claims to the antibody’s structure to some degree.200 
Including the antibody’s structure within a patent claim could be satisfied in a variety of ways, such as 
identifying particular amino acids that might be substituted within the protein sequence disclosed in the 
patent application, an exact description of an amino acid sequence, or a percent identity to an amino acid 
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variable domains of the heavy and light chains.202 These structural claims have always been useful in 
protecting antibodies that are innovative.203 It is highly likely that structural claims will continue to be 
useful in the future for those seeking to patent antibody medications following the Amgen decision, as 
using structural claims eliminates patentability for those who do not adequately disclose the antibody’s 
structure within the patent application and instead base their claims on the antibody’s function.204  
Moving forward with future attempts to patent antibodies, it has become significantly more 
important for patent applications to analyze each antibody on a case-by-case basis.205 Antibodies should 
be analyzed in this way so that patent applicants can determine which features should be claimed, and 
how the claims can be most effectively made based upon the amount of investment, data, and research 
pertaining to the antibody available.206 In carefully selecting and analyzing the features to be claimed, 
companies seeking patent protection in the future can increase the likelihood that at least some, if not all, 
of the claims made within their patent applications will remain patentable even when the patent faces 
invalidation.207 
Additionally, the court’s decision in Amgen will make the process of patenting antibodies for use 
in medications in the future far more expensive than they were previously. The process of developing 
antibody drugs is incredibly complex and very expensive.208 On average, medications that utilize 
antibodies cost around 2.6 billion dollars to bring to the market.209 In narrowing how antibodies can be 
patented with the Amgen decision, this process will likely become even more expensive for companies 
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written and enablement requirements post Amgen.210 Furthermore, in the process of developing these 
medications, it is possible that a company may have over 50 promising candidates at a time, which makes 
it more difficult for that company to know when to file a patent application.211 This is because the Amgen 
decision requires additional research and information to be presented to satisfy the written and 
enablement requirements, and if a company waits until they have that much information and have 
narrowed the promising antibody candidates to only a few, it is possible that someone else may have 
already filed an application overlapping with those antibody candidates.212 If someone had already filed 
an application overlapping with those candidates, this would lead to a waste of both time and money, 
making the process of developing antibody based medications more expensive. This increase in cost is 
simply another hurdle that those attempting to patent antibody drugs in the future will have to overcome. 
The Amgen decision drastically changed the antibody patenting process and created a plethora of 
questions that have yet to be answered. These questions have already made it much more difficult for 
attorneys working within patent law to know or understand exactly what to advise their clients who are 
hoping to patent antibodies to be used in various medications.213  The process of patenting antibodies is 
more difficult for attorneys following the Amgen decision because, although the Federal Circuit has said 
that it is theoretically possible to patent an antibody genus, the Federal Circuit has yet to provide an 
example of where the necessary requirements would be met in order for an antibody genus to be 
patented.214 Instead, the Federal Circuit has provided several instances where the written description and 
enablement requirements were not satisfied, such as stating that the 26 examples present in the Amgen 
decision and the 300  examples present in the AbbVie decision were not sufficient to satisfy these 
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written description and enablement requirements for those seeking patent protection of antibodies to be 
used in medication, this lack of clarification from the Federal Circuit creates a wide variety of problems 
for those companies that spend a substantial amount of money creating these medications.216 These 
problems and unanswered questions pose additional hurdles for patent applicants seeking protection over 
antibody medications. However many of these questions will likely be answered and some of these 
concepts will continue to receive attention from the court in the future, as issues with antibody drug patent 
claims continue to arise.217 
Conclusion 
In conclusion, the Amgen decision in 2021 drastically changed the U.S. patent system regarding 
the patentability of antibodies. In Amgen, the Federal Circuit held that broad functional claims were not 
sufficient to satisfy the enablement requirement.218 Ultimately, this decision provided a stark contrast to 
claims where antibodies used in medications had been patented in the past, given that broad functional 
claims had previously been considered acceptable in satisfying the enablement requirement.219 In 
providing this contrast, the Amgen decision raised the bar for protecting antibody inventions as the 
amount of data required when disclosing and claiming antibodies has significantly increased with the 
court’s decision in Amgen.220 The Amgen decision has and will continue to vastly impact the process and 
patentability of antibodies. inevitably making it more difficult for companies to obtain patents for 
antibody drugs. As a result of these difficulties created in the wake of the Amgen decision, some 
companies will instead turn to alternative methods to avoid these difficulties. However, the Amgen 
decision also will likely have several positive effects that will ultimately help patients, such as, those 
relating to competition, innovation, and lowering prices for patients. Moving forward, those looking to 
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patent antibodies in the future will instead have to tie their patent claims to the antibody’s structure to 
some degree.221 Additionally, companies seeking patent protection will need to carefully select and 
analyze the antibody features to be claimed to increase the likelihood that at least some, if not all, of the 
claims made within their patent applications will remain patentable even when the patent faces 
invalidation.222 The Amgen decision will also likely increase the cost to companies seeking to develop 
antibody drugs due to the additional research and information that are now required as a part of the patent 
application due to Amgen.223 However, despite these additional difficulties caused by Amgen and the shift 
that it has caused in the process and necessary requirements for patenting antibodies used in medications, 
pharmaceutical companies will likely still develop and create new antibody medications for years to 
come. Ultimately, drugs utilizing antibodies are some of the highest grossing drugs in the United States 
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